In NSCLC, co-occurring oncogenic driver mutations were identified in 61% of cases (N = 11 out of 18) including ALK, KRAS, BRAF, and EGFR (Supplementary Table S3). This evidence concerns the gene BRAF and non-small cell lung carcinoma.